Dupixent (dupilumab) Recommended for EU Approval by the CHMP to Treat Patients with COPD

31.05.2024 - Recommendation for adults with uncontrolled COPD with raised blood eosinophils based on data from two landmark Phase 3 trials demonstrating Dupixent significantly reduced exacerbations and improved lung function If approved, ...

Related Keywords

China ,Paris ,France General ,France ,Massachusetts ,United States ,Georged Yancopoulos ,Regeneron Velocimmune ,Regeneron Velocimmunetechnology ,Regeneron Genetics Center ,Drug Administration ,Euronext ,Regeneron Pharmaceuticals Inc ,European Commission Of Dupixent ,European Commission ,European Union ,Nasdaq ,Exchange Commission ,Dupilumab Development Program ,Clinical Research Program ,Us Department Of Justice ,Linkedin ,European Medicines Agency ,Human Use ,Respiratory Questionnaire ,Biologics License Application ,Chief Scientific Officer George ,Nasal Polyposis ,Forward Looking Statements ,Regeneron Pharmaceuticals ,Medicinal Products ,Product Candidates ,